Effect of circ72039 overexpression on gene expression related to gemcitabine sensitivity in pancreatic cancer cell lines

Understanding the molecular characteristics of gemcitabine sensitivity in pancreatic cancer is essential for advancing individualized treatment strategies. This study identifies circ720309 as a potential contributor to improve gemcitabine sensitivity. circ72309 decreased cytidine deaminase, a nucleoside enzyme which transforms gemcitabine into an inactive form, via reactive oxygen species activity, and increased solute carrier family 29 member 1 (SLC29A1), a nucleoside transporter which imports gemcitabine into cells, by regulating targeted miRNAs. Overall design: To identify circRNAs associated with gemcitabine sensitivity, a gemcitabine-resistant pancreatic cancer cell line (GR3) was established from MIAPaCa-2 and differences in circRNA expression between the two cell lines were examined.